Skip to main content
. 2017 Aug 10;5(3):46. doi: 10.3390/biomedicines5030046

Figure 7.

Figure 7

Efficacy of unmodified and PEGylated Ad5-dl1101/07 in immunocompetent hamsters. Hamsters with established HaK tumors were injected i.v. by the jugular route with a single dose 3 × 1010 vp of Ad5-dl1101/07 or Ad5-dl1101/07 5 kDa PEG. (A) Tumor volumes (n = 5 to 8 per group) were measured twice a week and the mean values were calculated from tumor dimensions and all individual tumor size; (B) Loss of survival as described in Figure 3.